| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 15 | 2022 | 219 | 1.640 |
Why?
|
| Brain Neoplasms | 12 | 2022 | 371 | 1.200 |
Why?
|
| Meningioma | 3 | 2020 | 54 | 1.170 |
Why?
|
| Medulla Oblongata | 3 | 2012 | 19 | 0.930 |
Why?
|
| Trigeminal Nerve Diseases | 1 | 2016 | 7 | 0.560 |
Why?
|
| Meningeal Neoplasms | 1 | 2016 | 42 | 0.540 |
Why?
|
| Gamma Rays | 1 | 2015 | 64 | 0.520 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 30 | 0.520 |
Why?
|
| Limonins | 1 | 2015 | 10 | 0.510 |
Why?
|
| Catechols | 1 | 2015 | 14 | 0.510 |
Why?
|
| Flavones | 1 | 2015 | 11 | 0.510 |
Why?
|
| Lanosterol | 1 | 2015 | 11 | 0.500 |
Why?
|
| Fatty Alcohols | 1 | 2015 | 14 | 0.500 |
Why?
|
| Heptanoic Acids | 1 | 2015 | 28 | 0.500 |
Why?
|
| Sesquiterpenes | 1 | 2015 | 41 | 0.500 |
Why?
|
| Apoptosis | 12 | 2020 | 1641 | 0.500 |
Why?
|
| Necrosis | 1 | 2015 | 239 | 0.500 |
Why?
|
| Radiation Injuries | 1 | 2015 | 97 | 0.500 |
Why?
|
| Arteries | 2 | 2005 | 108 | 0.490 |
Why?
|
| Triterpenes | 1 | 2015 | 40 | 0.490 |
Why?
|
| Glioma | 3 | 2020 | 140 | 0.460 |
Why?
|
| Cell Line, Tumor | 12 | 2020 | 1851 | 0.410 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2012 | 77 | 0.380 |
Why?
|
| Intracranial Aneurysm | 1 | 2012 | 87 | 0.370 |
Why?
|
| Allyl Compounds | 4 | 2018 | 29 | 0.360 |
Why?
|
| Sulfides | 4 | 2018 | 43 | 0.360 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2012 | 317 | 0.360 |
Why?
|
| Patient Care Team | 1 | 2012 | 311 | 0.350 |
Why?
|
| Hypertension | 3 | 2012 | 1535 | 0.320 |
Why?
|
| Skull Base | 4 | 2009 | 72 | 0.310 |
Why?
|
| Caspases | 5 | 2015 | 194 | 0.280 |
Why?
|
| Endoscopy | 5 | 2009 | 464 | 0.260 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2018 | 116 | 0.260 |
Why?
|
| Radioimmunotherapy | 1 | 2005 | 4 | 0.260 |
Why?
|
| Nerve Compression Syndromes | 1 | 2005 | 16 | 0.260 |
Why?
|
| Histone Deacetylases | 2 | 2018 | 99 | 0.250 |
Why?
|
| Radiopharmaceuticals | 1 | 2005 | 114 | 0.250 |
Why?
|
| Drug Delivery Systems | 2 | 2006 | 236 | 0.230 |
Why?
|
| Humans | 34 | 2022 | 68618 | 0.220 |
Why?
|
| Spinal Cord Injuries | 1 | 2009 | 551 | 0.210 |
Why?
|
| High Mobility Group Proteins | 1 | 2021 | 7 | 0.190 |
Why?
|
| Ependymoma | 1 | 2021 | 13 | 0.190 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2021 | 18 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2018 | 304 | 0.190 |
Why?
|
| Neurofibromin 2 | 1 | 2020 | 10 | 0.180 |
Why?
|
| Checkpoint Kinase 2 | 1 | 2020 | 14 | 0.180 |
Why?
|
| Mediator Complex | 1 | 2020 | 5 | 0.180 |
Why?
|
| Quinolones | 1 | 2020 | 60 | 0.170 |
Why?
|
| Pharmaceutical Preparations | 1 | 2020 | 101 | 0.170 |
Why?
|
| Neurosurgical Procedures | 2 | 2012 | 98 | 0.170 |
Why?
|
| Diabetes Mellitus | 1 | 2005 | 694 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 2 | 2016 | 511 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2020 | 756 | 0.170 |
Why?
|
| Benzimidazoles | 1 | 2020 | 128 | 0.170 |
Why?
|
| Calpain | 5 | 2007 | 205 | 0.160 |
Why?
|
| Cerebrospinal Fluid Rhinorrhea | 2 | 2009 | 41 | 0.160 |
Why?
|
| DNA Fragmentation | 3 | 2015 | 85 | 0.150 |
Why?
|
| Consciousness | 1 | 2018 | 17 | 0.150 |
Why?
|
| Blotting, Western | 4 | 2015 | 954 | 0.150 |
Why?
|
| Brain | 4 | 2020 | 2176 | 0.150 |
Why?
|
| Neurosurgery | 1 | 2018 | 42 | 0.150 |
Why?
|
| Male | 13 | 2018 | 37321 | 0.140 |
Why?
|
| Radiation | 1 | 2016 | 7 | 0.140 |
Why?
|
| Petrous Bone | 1 | 2016 | 1 | 0.140 |
Why?
|
| Medulloblastoma | 1 | 2016 | 24 | 0.140 |
Why?
|
| Neurons | 3 | 2018 | 881 | 0.140 |
Why?
|
| Peptide Hydrolases | 2 | 2007 | 82 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2016 | 82 | 0.140 |
Why?
|
| Middle Aged | 10 | 2012 | 21147 | 0.140 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 196 | 0.130 |
Why?
|
| Cell Proliferation | 2 | 2020 | 1174 | 0.130 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2015 | 57 | 0.130 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2015 | 64 | 0.130 |
Why?
|
| Dacarbazine | 2 | 2005 | 32 | 0.120 |
Why?
|
| Aged | 7 | 2012 | 14862 | 0.120 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2020 | 332 | 0.120 |
Why?
|
| Wnt Signaling Pathway | 1 | 2015 | 57 | 0.120 |
Why?
|
| Dexamethasone | 2 | 2005 | 150 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 852 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 3259 | 0.120 |
Why?
|
| Logistic Models | 2 | 2009 | 1420 | 0.110 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 163 | 0.110 |
Why?
|
| Adult | 8 | 2012 | 21403 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2013 | 33 | 0.110 |
Why?
|
| Female | 11 | 2012 | 38074 | 0.110 |
Why?
|
| Signal Transduction | 3 | 2020 | 2689 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 100 | 0.110 |
Why?
|
| Pneumocephalus | 2 | 2009 | 12 | 0.110 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2020 | 57 | 0.100 |
Why?
|
| Craniotomy | 2 | 2009 | 33 | 0.100 |
Why?
|
| Trigeminal Neuralgia | 1 | 2012 | 3 | 0.100 |
Why?
|
| Anesthesia, Inhalation | 1 | 2012 | 9 | 0.100 |
Why?
|
| Olivary Nucleus | 1 | 2012 | 4 | 0.100 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2012 | 7 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2005 | 2223 | 0.100 |
Why?
|
| Retrospective Studies | 6 | 2012 | 7277 | 0.100 |
Why?
|
| Caspase 3 | 4 | 2020 | 233 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2015 | 2083 | 0.100 |
Why?
|
| Sympathetic Nervous System | 1 | 2012 | 81 | 0.100 |
Why?
|
| Biomarkers, Tumor | 1 | 2015 | 508 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2018 | 596 | 0.100 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2016 | 84 | 0.100 |
Why?
|
| Garlic | 2 | 2012 | 12 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2005 | 1553 | 0.100 |
Why?
|
| Cell Survival | 6 | 2016 | 901 | 0.100 |
Why?
|
| Electric Stimulation | 1 | 2012 | 218 | 0.100 |
Why?
|
| Cerebrovascular Disorders | 1 | 2012 | 182 | 0.090 |
Why?
|
| Risk Factors | 4 | 2012 | 5731 | 0.090 |
Why?
|
| Functional Laterality | 1 | 2012 | 240 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2012 | 201 | 0.090 |
Why?
|
| bcl-2-Associated X Protein | 4 | 2020 | 111 | 0.090 |
Why?
|
| Heart Rate | 1 | 2012 | 568 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2020 | 223 | 0.080 |
Why?
|
| Encephalocele | 1 | 2009 | 30 | 0.080 |
Why?
|
| Rats | 2 | 2015 | 5300 | 0.080 |
Why?
|
| Poisson Distribution | 1 | 2009 | 85 | 0.080 |
Why?
|
| Apoptosis Regulatory Proteins | 4 | 2013 | 100 | 0.080 |
Why?
|
| Antineoplastic Agents | 2 | 2006 | 1070 | 0.080 |
Why?
|
| Animals | 6 | 2018 | 20881 | 0.080 |
Why?
|
| Adolescent | 4 | 2009 | 8912 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 546 | 0.070 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 122 | 0.070 |
Why?
|
| Aminolevulinic Acid | 1 | 2007 | 5 | 0.070 |
Why?
|
| Disulfides | 1 | 2007 | 40 | 0.070 |
Why?
|
| Treatment Outcome | 2 | 2012 | 7029 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2009 | 285 | 0.070 |
Why?
|
| DNA Modification Methylases | 2 | 2020 | 24 | 0.070 |
Why?
|
| Benzamides | 2 | 2020 | 156 | 0.070 |
Why?
|
| Pituitary Neoplasms | 1 | 2007 | 52 | 0.070 |
Why?
|
| DNA Repair Enzymes | 2 | 2020 | 53 | 0.070 |
Why?
|
| Photochemotherapy | 1 | 2007 | 59 | 0.070 |
Why?
|
| Mass Screening | 1 | 2012 | 843 | 0.070 |
Why?
|
| Curcumin | 1 | 2006 | 23 | 0.070 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 1 | 2007 | 62 | 0.070 |
Why?
|
| Postoperative Complications | 3 | 2009 | 1615 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2012 | 174 | 0.070 |
Why?
|
| Immunotoxins | 1 | 2006 | 23 | 0.070 |
Why?
|
| Radioisotopes | 1 | 2006 | 40 | 0.070 |
Why?
|
| South Carolina | 2 | 2012 | 2752 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2012 | 1451 | 0.070 |
Why?
|
| Time Factors | 3 | 2016 | 4655 | 0.070 |
Why?
|
| Mice, SCID | 2 | 2018 | 238 | 0.060 |
Why?
|
| Karnofsky Performance Status | 1 | 2005 | 4 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2020 | 194 | 0.060 |
Why?
|
| Stereotaxic Techniques | 1 | 2005 | 35 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2006 | 248 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2020 | 331 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2005 | 249 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 137 | 0.060 |
Why?
|
| NF-kappa B | 3 | 2016 | 432 | 0.060 |
Why?
|
| Graft Survival | 1 | 2007 | 465 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2020 | 331 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2004 | 99 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 468 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2018 | 1745 | 0.060 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2005 | 234 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2005 | 652 | 0.050 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 1046 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2016 | 1040 | 0.050 |
Why?
|
| Free Radical Scavengers | 1 | 2003 | 112 | 0.050 |
Why?
|
| Infarction, Middle Cerebral Artery | 1 | 2003 | 105 | 0.050 |
Why?
|
| Preservation, Biological | 1 | 2022 | 11 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2005 | 342 | 0.050 |
Why?
|
| Tissue Preservation | 1 | 2022 | 44 | 0.050 |
Why?
|
| Mitochondria | 1 | 2006 | 643 | 0.050 |
Why?
|
| RNA | 1 | 2022 | 171 | 0.050 |
Why?
|
| Protein Domains | 1 | 2021 | 74 | 0.050 |
Why?
|
| Sulfones | 1 | 2020 | 45 | 0.050 |
Why?
|
| Cloning, Molecular | 1 | 2021 | 357 | 0.050 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2020 | 22 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2020 | 11 | 0.050 |
Why?
|
| bcl-X Protein | 1 | 2020 | 36 | 0.050 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 213 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2007 | 791 | 0.040 |
Why?
|
| Reperfusion Injury | 1 | 2003 | 320 | 0.040 |
Why?
|
| Triazines | 1 | 2020 | 48 | 0.040 |
Why?
|
| Acetylcysteine | 1 | 2003 | 296 | 0.040 |
Why?
|
| Stroke | 1 | 2012 | 2163 | 0.040 |
Why?
|
| Imidazoles | 1 | 2020 | 175 | 0.040 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2013 | 160 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2020 | 1664 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2020 | 178 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2020 | 525 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 800 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 1342 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2020 | 431 | 0.040 |
Why?
|
| 4-1BB Ligand | 1 | 2016 | 5 | 0.040 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2016 | 52 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 951 | 0.030 |
Why?
|
| Incidence | 2 | 2012 | 1603 | 0.030 |
Why?
|
| Mitochondrial Proteins | 2 | 2007 | 113 | 0.030 |
Why?
|
| Spectrin | 2 | 2007 | 17 | 0.030 |
Why?
|
| Astrocytes | 1 | 2018 | 270 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 129 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2005 | 4848 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 219 | 0.030 |
Why?
|
| Mutation | 1 | 2020 | 1213 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2015 | 84 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 499 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2015 | 152 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2015 | 222 | 0.030 |
Why?
|
| Child | 3 | 2009 | 6405 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2012 | 37 | 0.030 |
Why?
|
| Calcium | 2 | 2007 | 929 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2009 | 3187 | 0.020 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2012 | 71 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 64 | 0.020 |
Why?
|
| Flavonoids | 1 | 2012 | 109 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 84 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 120 | 0.020 |
Why?
|
| DNA Repair | 1 | 2012 | 127 | 0.020 |
Why?
|
| Retinoids | 1 | 2012 | 122 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2012 | 434 | 0.020 |
Why?
|
| Disease Progression | 1 | 2013 | 1038 | 0.020 |
Why?
|
| Skull Neoplasms | 1 | 2009 | 23 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 2324 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2009 | 86 | 0.020 |
Why?
|
| Mice | 2 | 2013 | 8474 | 0.020 |
Why?
|
| Meningitis | 1 | 2008 | 23 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2009 | 216 | 0.020 |
Why?
|
| Surgical Flaps | 1 | 2009 | 120 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 100 | 0.020 |
Why?
|
| Liver | 1 | 2013 | 1118 | 0.020 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2007 | 28 | 0.020 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2007 | 4 | 0.020 |
Why?
|
| I-kappa B Proteins | 1 | 2007 | 47 | 0.020 |
Why?
|
| Apoptosis Inducing Factor | 1 | 2007 | 10 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2007 | 75 | 0.020 |
Why?
|
| Plant Oils | 1 | 2007 | 31 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2007 | 88 | 0.020 |
Why?
|
| Tretinoin | 1 | 2007 | 92 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 40 | 0.020 |
Why?
|
| Anticarcinogenic Agents | 1 | 2007 | 52 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2007 | 140 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2012 | 447 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2007 | 294 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2007 | 89 | 0.020 |
Why?
|
| Staining and Labeling | 1 | 2006 | 144 | 0.020 |
Why?
|
| Molecular Weight | 1 | 2006 | 358 | 0.020 |
Why?
|
| Infusion Pumps | 1 | 2006 | 39 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2007 | 109 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 216 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 2550 | 0.020 |
Why?
|
| Blood-Brain Barrier | 1 | 2006 | 99 | 0.020 |
Why?
|
| Trypan Blue | 1 | 2005 | 24 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 659 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 2002 | 32 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2002 | 31 | 0.010 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2003 | 201 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 163 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 2002 | 114 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2007 | 2673 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2002 | 282 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 710 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 1174 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2003 | 626 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2003 | 384 | 0.010 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 411 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2002 | 682 | 0.010 |
Why?
|
| Young Adult | 1 | 2009 | 5717 | 0.010 |
Why?
|